Cargando…

Follicular lymphoma: an Institutional Analysis

BACKGROUND: Follicular lymphoma (FL) is second most common lymphoma in adult, constituted 20% of all lymphoma cases in the west. There is limited information is available on FL from India. METHODS: The clinico-pathological profile, treatment outcome and prognostic factors for survival were assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Gogia, Ajay, Raina, Vinod, Kumar, Lalit, Sharma, Atul, Sharma, Mehar Chand, Mallick, Saumya Ranjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464484/
https://www.ncbi.nlm.nih.gov/pubmed/28440975
http://dx.doi.org/10.22034/APJCP.2017.18.3.681
_version_ 1783242777681723392
author Gogia, Ajay
Raina, Vinod
Kumar, Lalit
Sharma, Atul
Sharma, Mehar Chand
Mallick, Saumya Ranjan
author_facet Gogia, Ajay
Raina, Vinod
Kumar, Lalit
Sharma, Atul
Sharma, Mehar Chand
Mallick, Saumya Ranjan
author_sort Gogia, Ajay
collection PubMed
description BACKGROUND: Follicular lymphoma (FL) is second most common lymphoma in adult, constituted 20% of all lymphoma cases in the west. There is limited information is available on FL from India. METHODS: The clinico-pathological profile, treatment outcome and prognostic factors for survival were assessed retrospectively in 181 patients of FL seen at our center over a period of 17 years (1996-2012). RESULTS: There were 120 males and 61 females. The median age was 51 years (24-80 years). The common presenting features were lymphadenopathy 71%, fatigue 23% and fever 20%. Ann Arbor stage distribution was: stage I - 9%, stage II - 11%, stage III -22 % and stage IV - 58%. Extra nodal involvement and bulky disease were present in 22% and 19% patients respectively. Follicular Lymphoma International Prognostic Index (FLIPI) 1 score : Low -25%, Intermediate-45% and high risk in 30% of cases. One forty five patients (80%) received treatment at presentation or during follow-up. Chemotherapeutic regimen used were: CHOP-45, CVP-51, chlorambucil and prednisolone -7, BR (bendamustine and rituximab)-12, RCHOP- 14 RCVP – 7 and other regimen were used in 5 cases. The overall response (ORR) and complete remission (CR) rates were 70% and 35% respectively. Median overall survival (OS) and event free survival (EFS) was 5.5 years and 2.5 years respectively, with median follow up period of 3.0 years. Grade 3 histology, failure to attain CR, low serum albumin, and high risk FLIPI were significantly associated with lower event free survival. High risk FLIPI (HR 1.46, 95% CI 1.03-2.10, p=0.003) and failure to attain CR (HR 2.64, CI 1.10-4.30, p=0.001) were predictors of poor OS. CONCLUSIONS: FL represents 9 % of all lymphoma in adult. This is the largest data from single institute from India. Eighty percentage of patients presented in stage III/IV disease. High risk FLIPI and failure to attain CR were important prognostic variables for OS.
format Online
Article
Text
id pubmed-5464484
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-54644842017-08-28 Follicular lymphoma: an Institutional Analysis Gogia, Ajay Raina, Vinod Kumar, Lalit Sharma, Atul Sharma, Mehar Chand Mallick, Saumya Ranjan Asian Pac J Cancer Prev Research Article BACKGROUND: Follicular lymphoma (FL) is second most common lymphoma in adult, constituted 20% of all lymphoma cases in the west. There is limited information is available on FL from India. METHODS: The clinico-pathological profile, treatment outcome and prognostic factors for survival were assessed retrospectively in 181 patients of FL seen at our center over a period of 17 years (1996-2012). RESULTS: There were 120 males and 61 females. The median age was 51 years (24-80 years). The common presenting features were lymphadenopathy 71%, fatigue 23% and fever 20%. Ann Arbor stage distribution was: stage I - 9%, stage II - 11%, stage III -22 % and stage IV - 58%. Extra nodal involvement and bulky disease were present in 22% and 19% patients respectively. Follicular Lymphoma International Prognostic Index (FLIPI) 1 score : Low -25%, Intermediate-45% and high risk in 30% of cases. One forty five patients (80%) received treatment at presentation or during follow-up. Chemotherapeutic regimen used were: CHOP-45, CVP-51, chlorambucil and prednisolone -7, BR (bendamustine and rituximab)-12, RCHOP- 14 RCVP – 7 and other regimen were used in 5 cases. The overall response (ORR) and complete remission (CR) rates were 70% and 35% respectively. Median overall survival (OS) and event free survival (EFS) was 5.5 years and 2.5 years respectively, with median follow up period of 3.0 years. Grade 3 histology, failure to attain CR, low serum albumin, and high risk FLIPI were significantly associated with lower event free survival. High risk FLIPI (HR 1.46, 95% CI 1.03-2.10, p=0.003) and failure to attain CR (HR 2.64, CI 1.10-4.30, p=0.001) were predictors of poor OS. CONCLUSIONS: FL represents 9 % of all lymphoma in adult. This is the largest data from single institute from India. Eighty percentage of patients presented in stage III/IV disease. High risk FLIPI and failure to attain CR were important prognostic variables for OS. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5464484/ /pubmed/28440975 http://dx.doi.org/10.22034/APJCP.2017.18.3.681 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Gogia, Ajay
Raina, Vinod
Kumar, Lalit
Sharma, Atul
Sharma, Mehar Chand
Mallick, Saumya Ranjan
Follicular lymphoma: an Institutional Analysis
title Follicular lymphoma: an Institutional Analysis
title_full Follicular lymphoma: an Institutional Analysis
title_fullStr Follicular lymphoma: an Institutional Analysis
title_full_unstemmed Follicular lymphoma: an Institutional Analysis
title_short Follicular lymphoma: an Institutional Analysis
title_sort follicular lymphoma: an institutional analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464484/
https://www.ncbi.nlm.nih.gov/pubmed/28440975
http://dx.doi.org/10.22034/APJCP.2017.18.3.681
work_keys_str_mv AT gogiaajay follicularlymphomaaninstitutionalanalysis
AT rainavinod follicularlymphomaaninstitutionalanalysis
AT kumarlalit follicularlymphomaaninstitutionalanalysis
AT sharmaatul follicularlymphomaaninstitutionalanalysis
AT sharmameharchand follicularlymphomaaninstitutionalanalysis
AT mallicksaumyaranjan follicularlymphomaaninstitutionalanalysis